Estradiol/levonorgestrel sequential transdermal - Merck KGaA

Drug Profile

Estradiol/levonorgestrel sequential transdermal - Merck KGaA

Alternative Names: EMD-59265; Fem7 Combi

Latest Information Update: 09 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnanes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 31 Dec 2002 Fem7® Combi has been licensed to Gedeon Richter in many Central European, Eastern European and Commonwealth of Independent States countries
  • 27 May 2002 A study has been added to the adverse events and Women's Health therapeutic trials sections
  • 15 Nov 2001 Launched for Menopausal syndrome in France (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top